Medtronic expects Cardiac Ablation Solutions to reach a $2 billion trailing revenue mark in fiscal Q1 2027 as the Affera installed base expands.
Medtronic expects Symplicity renal denervation to provide a strong growth lift to Cardiovascular in fiscal 2027 as reimbursement and procedure adoption build.
Medtronic expects Altaviva to continue scaling into fiscal 2027, making Pelvic Health a Neuroscience growth contributor.
Medtronic expects Stealth AXiS platform sales to drive consumables pull-through in Cranial & Spinal Technologies as the new navigation-robotics platform ramps.
Medtronic expects the U.S. commercial launch of MiniMed Flex in summer 2026 to support its Diabetes innovation cycle.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Medtronic plc and 4,900+ companies.